Request Demo
LEO and DEBRA Research partner to advance epidermolysis bullosa treatments
Drug Approval
LEO Pharma and non-profit organisation DEBRA Research have announced a collaboration aimed at accelerating the development of treatments for epidermolysis bullosa (EB).
LEO Pharmaclusive strategic partnershipDEBRA ResearchLEO’s experience in medical dermatology with DEBRA’s focus on EB patient care and pharmaepidermolysis bullosa (EB)
Though financial details of the alliance have not been disclosed, the partners said they are hopinDEBRA“enhance scouting capabilities and provide additional capacity to accelerate the development of life-changing therapies for EB”.
There is currently no cure for EB, a group of rare and painful inherited skin disorders that cause the skin to become very fragile and tear or blister very easily. Treatments are limited to relieving symptoms and preventing complications developing, such as infection.
Jacob Pontoppidan Thyssen, chief scientific officer and executiinherited skin disorders, said: “Having personally cared for patients with severe EB, I have experienced the devastating consequences firsthand.”infection
He continued: “We are proud to collaborate with DEBRA Research, whose vast experience in the pharmaceutical industry and commitment to advancing medical research are invaluable. Together, we can do so much more.”
Also commenting on the partnership, Hubert TruebDEBRA Researchirector at DEBRA Research, said: “This collaboration provides an excellent opportunity for us to combine our expertise and resources, enabling us to make meaningful advancements in the battle against EB. We are excited about the potential impact of this partnership…”
The announcement comes less than a month after LEO partnered with Gilead DEBRA Researchvance its small molecule oral STAT6 programme for inflammatory diseases.
The deal, worth $1.7bn, gave Gilead global righLEOto develop, manuGilead Sciencesmercialise the oral STAT6 programme.STAT6while, LEO willinflammatory diseasesl rights to STAT6 topical formulations in dermatology, and will have the option to co-commercialise oral programmes for dermatology indications outside the US.
The company also recently recGileadan approval from the Medicines and Healthcare Products Regulatory STAT6y for its Anzupgo (delgLEOtinib) cream in chronic hand eczema. TSTAT6eatment was specifically authorised for use in adults with moderate-to-severe cases of the inflammatory skin disease for whom topical corticosteroids are inadequate or inappropriate.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
-Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!